JP7174691B2 - 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用 - Google Patents

抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用 Download PDF

Info

Publication number
JP7174691B2
JP7174691B2 JP2019510931A JP2019510931A JP7174691B2 JP 7174691 B2 JP7174691 B2 JP 7174691B2 JP 2019510931 A JP2019510931 A JP 2019510931A JP 2019510931 A JP2019510931 A JP 2019510931A JP 7174691 B2 JP7174691 B2 JP 7174691B2
Authority
JP
Japan
Prior art keywords
vegf
ang
bispecific antibody
binding domain
h1rk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528694A5 (enExample
JP2019528694A (ja
Inventor
チン レオウ，チン
ディマシ，ナッザレノ
コフマン，カレン
フレミング，ライアン
ツイ，ピン
ガオ，チャンショウ
セペダ，マリオ，エー
ミッテルマン，エイドリアン シュワルツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2019528694A publication Critical patent/JP2019528694A/ja
Publication of JP2019528694A5 publication Critical patent/JP2019528694A5/ja
Application granted granted Critical
Publication of JP7174691B2 publication Critical patent/JP7174691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019510931A 2016-08-23 2017-08-22 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用 Active JP7174691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378388P 2016-08-23 2016-08-23
US62/378,388 2016-08-23
PCT/EP2017/071104 WO2018037000A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a and anti-ang2 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2019528694A JP2019528694A (ja) 2019-10-17
JP2019528694A5 JP2019528694A5 (enExample) 2020-10-01
JP7174691B2 true JP7174691B2 (ja) 2022-11-17

Family

ID=59714013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510931A Active JP7174691B2 (ja) 2016-08-23 2017-08-22 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用

Country Status (10)

Country Link
US (2) US10836819B2 (enExample)
EP (1) EP3504237A1 (enExample)
JP (1) JP7174691B2 (enExample)
KR (1) KR102543878B1 (enExample)
CN (1) CN109863171B (enExample)
AU (1) AU2017315075B2 (enExample)
CA (1) CA3034574A1 (enExample)
IL (1) IL264962B2 (enExample)
MA (1) MA46036A (enExample)
WO (1) WO2018037000A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
US20240239881A1 (en) * 2020-06-22 2024-07-18 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and its usage
CR20230114A (es) 2020-09-04 2023-05-18 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y métodos de uso
EP4313148A4 (en) * 2021-03-30 2025-02-19 Abpro Corporation METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
WO2023212361A1 (en) 2022-04-29 2023-11-02 inQB8 Medical Technologies, LLC Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US11883030B2 (en) 2022-04-29 2024-01-30 inQB8 Medical Technologies, LLC Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
WO2024085606A1 (ko) * 2022-10-20 2024-04-25 (주)니오테스바이오 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523841A (ja) 2004-12-21 2008-07-10 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
JP2012504943A (ja) 2008-10-08 2012-03-01 エフ．ホフマン−ラ ロシュ アーゲー 二重特異的抗−ｖｅｇｆ／抗−ａｎｇ−２抗体
JP2013526848A (ja) 2010-03-26 2013-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性二価抗ｖｅｇｆ／抗ａｎｇ−２抗体
US20160215045A1 (en) 2015-01-28 2016-07-28 Eli Lilly And Company VEGFA/Ang2 Compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
PL359653A1 (en) 2000-06-23 2004-08-23 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP5179373B2 (ja) * 2005-12-15 2013-04-10 アストラゼネカ アクチボラグ 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP2247305A4 (en) * 2008-01-28 2012-11-14 Medimmune Ltd STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102250248A (zh) * 2011-06-15 2011-11-23 常州亚当生物技术有限公司 抗vegf/ang2双特异性抗体及其应用
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
SG11201408538PA (en) * 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR20150063847A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-A/항 Ang2 이중 특이 항체
CA2946906A1 (en) * 2014-05-07 2015-11-12 Medimmune, Llc Methods of using anti-ang2 antibodies
SG11201703428SA (en) * 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523841A (ja) 2004-12-21 2008-07-10 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
JP2012504943A (ja) 2008-10-08 2012-03-01 エフ．ホフマン−ラ ロシュ アーゲー 二重特異的抗−ｖｅｇｆ／抗−ａｎｇ−２抗体
JP2013526848A (ja) 2010-03-26 2013-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性二価抗ｖｅｇｆ／抗ａｎｇ−２抗体
US20160215045A1 (en) 2015-01-28 2016-07-28 Eli Lilly And Company VEGFA/Ang2 Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Applied Biochemistry and Biotechnology，2008年01月，Vol 144, No. 1，p. 15-26

Also Published As

Publication number Publication date
IL264962A (en) 2019-05-30
US20190194308A1 (en) 2019-06-27
KR102543878B1 (ko) 2023-06-14
US20210040194A1 (en) 2021-02-11
IL264962B1 (en) 2024-05-01
CN109863171A (zh) 2019-06-07
MA46036A (fr) 2019-07-03
AU2017315075B2 (en) 2020-10-01
KR20190039577A (ko) 2019-04-12
WO2018037000A1 (en) 2018-03-01
US11566068B2 (en) 2023-01-31
US10836819B2 (en) 2020-11-17
CN109863171B (zh) 2023-08-04
EP3504237A1 (en) 2019-07-03
AU2017315075A1 (en) 2019-04-04
IL264962B2 (en) 2024-09-01
CA3034574A1 (en) 2018-03-01
JP2019528694A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7174691B2 (ja) 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用
CN109451728A (zh) 抗pacap抗体及其用途
JP7076082B2 (ja) 新規な抗ヒトｇｐｖｉ抗体およびその使用
JP2018504893A (ja) Ｂｍｐ６を標的とする抗体のための組成物および方法
JP7277531B2 (ja) 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用
KR20240004694A (ko) 항체
HK40008334A (en) Anti-vegf-a and anti-ang2 antibodies and uses thereof
HK40008334B (zh) 抗vegf-a和抗ang2抗体及其用途
HK40047851A (en) Anti-vegf-a antibodies and uses thereof
HK40010498A (en) Anti-vegf-a antibodies and uses thereof
HK40010498B (en) Anti-vegf-a antibodies and uses thereof
HK40008333B (en) Anti-vegf-a antibodies and uses thereof
HK40008333A (en) Anti-vegf-a antibodies and uses thereof
JP2023527916A (ja) アゴニスト抗ｃｄ４０抗体
EA039579B1 (ru) Способы и композиции антител, направленных против bmp6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220727

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220803

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221107

R150 Certificate of patent or registration of utility model

Ref document number: 7174691

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150